Outlook Therapeutics Inc [OTLK] stock prices are up 5.27% to $0.94 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The OTLK shares have lost -14.22% over the last week, with a monthly amount drifted -50.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Outlook Therapeutics Inc [NASDAQ: OTLK] stock has seen the most recent analyst activity on August 29, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Guggenheim downgraded its rating to Neutral on August 28, 2025. On December 02, 2024, downgrade downgraded it’s rating to Neutral. BTIG Research upgraded its rating to a Buy but stick to its price target of $50 on March 27, 2024. Chardan Capital Markets upgraded its rating to a Buy but $3 remained the price target by the analyst firm on February 15, 2024. Guggenheim upgraded its rating to Buy for this stock on January 25, 2024. In a note dated December 27, 2023, CapitalOne upgraded an Overweight rating on this stock but restated the target price of $5.
The stock price of Outlook Therapeutics Inc [OTLK] has been fluctuating between $0.79 and $8.32 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Outlook Therapeutics Inc [NASDAQ: OTLK] shares were valued at $0.94 at the most recent close of the market. An investor can expect a potential return of 6.38% based on the average OTLK price forecast.
Analyzing the OTLK fundamentals
Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at -43.35%, Pretax Profit Margin comes in at -25.93%, and Net Profit Margin reading is -25.93%. To continue investigating profitability, this company’s Return on Assets is posted at -1.94, Equity is 0.9 and Total Capital is 7.98. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8700 points at the first support level, and at 0.8050 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9900, and for the 2nd resistance point, it is at 1.0450.
Ratios To Look Out For
It’s worth pointing out that Outlook Therapeutics Inc [NASDAQ:OTLK]’s Current Ratio is 0.67. As well, the Quick Ratio is 0.54, while the Cash Ratio is 0.28. Considering the valuation of this stock, the price to sales ratio is 27.50.
Transactions by insiders
Recent insider trading involved KENYON LAWRENCE A, Chief Financial Officer, that happened on Sep 26 ’24 when 5000.0 shares were purchased.
